CD39 controls a rate-limiting step for the synthesis of adenosine, which inhibits a series of antitumor processes in the tumor microenvironment by targeting T cells, NK cells, macrophages, and DCs68,69. The gene discussed is ENTPD1; the disease is neoplasm.